RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $34.29 million. The enterprise value is $29.91 million.
Market Cap | 34.29M |
Enterprise Value | 29.91M |
Important Dates
The last earnings date was Friday, May 10, 2024, before market open.
Earnings Date | May 10, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 23.95 million shares outstanding. The number of shares has increased by 64.44% in one year.
Shares Outstanding | 23.95M |
Shares Change (YoY) | +64.44% |
Shares Change (QoQ) | +39.72% |
Owned by Insiders (%) | 6.89% |
Owned by Institutions (%) | 1.38% |
Float | 15.82M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 19.41 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.38, with zero debt.
Current Ratio | 4.38 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -73.55 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -200.20% |
Return on Capital (ROIC) | -600.51% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.01M |
Employee Count | 8 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.76% in the last 52 weeks. The beta is 1.07, so RenovoRx's price volatility has been similar to the market average.
Beta (1Y) | 1.07 |
52-Week Price Change | -34.76% |
50-Day Moving Average | 1.32 |
200-Day Moving Average | 1.30 |
Relative Strength Index (RSI) | 53.51 |
Average Volume (30 Days) | 37,130 |
Short Selling Information
The latest short interest is 39,434, so 0.16% of the outstanding shares have been sold short.
Short Interest | 39,434 |
Short Previous Month | 65,482 |
Short % of Shares Out | 0.16% |
Short % of Float | 0.25% |
Short Ratio (days to cover) | 0.67 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -10.61M |
Pretax Income | -8.05M |
Net Income | -8.05M |
EBITDA | -7.94M |
EBIT | -7.94M |
Earnings Per Share (EPS) | -$0.72 |
Balance Sheet
The company has $4.39 million in cash and no debt, giving a net cash position of $4.39 million or $0.18 per share.
Cash & Cash Equivalents | 4.39M |
Total Debt | n/a |
Net Cash | 4.39M |
Net Cash Per Share | $0.18 |
Equity / Book Value | 1.77M |
Book Value Per Share | 0.07 |
Working Capital | 3.70M |
Cash Flow
Operating Cash Flow | -9.76M |
Capital Expenditures | n/a |
Free Cash Flow | -9.76M |
FCF Per Share | -$0.65 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -64.44% |
Shareholder Yield | -64.44% |
Earnings Yield | -23.48% |
FCF Yield | -28.45% |
Analyst Forecast
The average price target for RenovoRx is $4.00, which is 191.97% higher than the current price. The consensus rating is "Buy".
Price Target | $4.00 |
Price Target Difference | 191.97% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |